Loading...
LeMaitre Vascular Q1 2025 Earnings Report
LeMaitre Vascular reported its Q1 2025 financial results, announced a quarterly dividend, and provided guidance.
Key Takeaways
LeMaitre Vascular reported strong Q1 2025 results with sales up 12% organically, driven by growth in grafts and carotid shunts. The company increased its full-year sales guidance and highlighted its strategic optionality due to a strong cash position.
Sales increased by 12% to $59.9 million, with organic growth at 13%.
Gross margin improved to 69.2%, up 60 basis points from the prior year.
Operating income grew 6% to $12.6 million, resulting in an operating margin of 21%.
Diluted earnings per share rose 10% to $0.48, and cash increased sequentially to $302.5 million.
Revenue by Geographic Location
Forward Guidance
LeMaitre Vascular increased its full-year 2025 sales guidance and provided Q2 2025 guidance, reflecting continued positive momentum and strategic flexibility.
Positive Outlook
- Increased full-year 2025 reported sales guidance to $242mm - $249mm (midpoint $245mm), up from prior guidance of $239mm.
- Full-year 2025 organic sales growth guidance increased to 13%, up from 10%.
- Q2 2025 sales guidance set at $61.5mm - $63.5mm (midpoint $62.5mm), representing 12% organic growth.
- Q2 2025 operating income guidance of $14.6mm - $16.0mm (midpoint $15.3mm), indicating 7% growth.
- Full-year 2025 EPS guidance of $2.07 - $2.24 (midpoint $2.16), representing 12% growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...